KR102193317B1 - Composition for obesity treatment and improvement - Google Patents
Composition for obesity treatment and improvement Download PDFInfo
- Publication number
- KR102193317B1 KR102193317B1 KR1020190028351A KR20190028351A KR102193317B1 KR 102193317 B1 KR102193317 B1 KR 102193317B1 KR 1020190028351 A KR1020190028351 A KR 1020190028351A KR 20190028351 A KR20190028351 A KR 20190028351A KR 102193317 B1 KR102193317 B1 KR 102193317B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- group
- weight
- obesity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 208000008589 Obesity Diseases 0.000 title claims abstract description 42
- 235000020824 obesity Nutrition 0.000 title claims abstract description 42
- 230000006872 improvement Effects 0.000 title abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 141
- 229940107605 borage extract Drugs 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 24
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 241001072256 Boraginaceae Species 0.000 claims description 11
- 235000007689 Borago officinalis Nutrition 0.000 claims description 11
- 108010016731 PPAR gamma Proteins 0.000 claims description 10
- 230000003579 anti-obesity Effects 0.000 claims description 10
- 241000305599 Erigeron annuus Species 0.000 claims description 4
- 241000983851 Hosta longipes Species 0.000 claims description 4
- 241000476395 Indigofera bungeana Species 0.000 claims description 4
- 241001279838 Pachysandra terminalis Species 0.000 claims description 4
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- 210000000577 adipose tissue Anatomy 0.000 abstract description 12
- 230000037396 body weight Effects 0.000 abstract description 10
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 244000269722 Thea sinensis Species 0.000 abstract description 7
- 210000001789 adipocyte Anatomy 0.000 abstract description 7
- 230000004069 differentiation Effects 0.000 abstract description 7
- 102000040945 Transcription factor Human genes 0.000 abstract description 6
- 108091023040 Transcription factor Proteins 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 235000020542 functional tea Nutrition 0.000 abstract description 3
- 235000009200 high fat diet Nutrition 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000002386 leaching Methods 0.000 description 9
- 108010065459 CCAAT-Enhancer-Binding Protein-alpha Proteins 0.000 description 8
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000004334 sorbic acid Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 239000004148 curcumin Substances 0.000 description 7
- 201000010063 epididymitis Diseases 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000011759 adipose tissue development Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000593508 Garcinia Species 0.000 description 2
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 241000534017 Saururus chinensis Species 0.000 description 2
- 244000185386 Thladiantha grosvenorii Species 0.000 description 2
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008204 material by function Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000021038 drupes Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F2200/00—Special features
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
본 발명은 일년봉 추출물 및 보리지 추출물을 유효성분으로 포함하며, 낭아초 추출물, 수호초 추출물, 비비추 및 이들의 혼합물로 이루어진 군으로부터 선택되는 천연 추출물을 추가로 포함하는 비만 치료 및 개선용 조성물이 제공된다.
상기 조성물은 지방세포분화와 관련된 전사인자의 발현을 적절히 조절함으로써 체중 및 체지방 감소와 혈중 지질 수치를 더욱 효과적으로 개선할 수 있다. 이러한 효과를 바탕으로 하여, 종래의 물질을 대체한 약학 조성물, 기능성 식품 및 차(茶)로 이용될 수 있다.The present invention provides a composition for the treatment and improvement of obesity, comprising an annual bark extract and a borage extract as an active ingredient, and further comprising a natural extract selected from the group consisting of cystweed extract, suhoweed extract, bibichu, and mixtures thereof do.
The composition can more effectively reduce body weight and body fat and improve blood lipid levels by appropriately controlling the expression of transcription factors related to adipocyte differentiation. Based on this effect, it can be used as a pharmaceutical composition, functional food, and tea replacing conventional substances.
Description
본 발명은 비만 치료 및 개선용 조성물에 관한 것으로, 천연 추출물로 부작용이나 세포독성에 대한 위험이 없으며, 지방 세포 분화와 관련된 전사인자의 발현을 조절함으로써, 체중 및 체지방 감소와 혈중 지질 수치 개선 효과가 있는 비만 치료 및 개선용 조성물에 관한 것이다.The present invention relates to a composition for the treatment and improvement of obesity, as a natural extract, there is no risk of side effects or cytotoxicity, and by controlling the expression of transcription factors related to adipocyte differentiation, the effect of reducing body weight and body fat and improving blood lipid levels is It relates to a composition for treating and improving obesity.
비만(obesity)은 과다한 열량 섭취와 운동부족이 주된 원인이지만 그 외에도 사회적, 유전적, 환경적인 요인 등이 영향을 미치는 복합증후군으로, 음식의 섭취 량과 에너지 소비의 불균형으로 인해 체내 지방이 과잉 축적되어 있어 여러 건강상의 문제들을 야기할 수 있는 상태를 말한다.Obesity is a complex syndrome that is mainly caused by excessive caloric intake and lack of exercise, but other factors such as social, genetic, and environmental factors affect the body's excessive fat accumulation due to imbalance in food intake and energy consumption. It is a condition that can cause various health problems.
그 원인은 과다한 영양섭취, 신체활동 부족 등 생활방식으로 인한 경우가 대부분이며, 드물게는 약물 복용이나 질환에 의해 2차적으로 발생할 수 있다.The cause is mostly due to lifestyles such as excessive nutritional intake and lack of physical activity, and in rare cases, it can be secondary to medication or disease.
비만은 그 자체가 갖는 문제점뿐만 아니라 당뇨, 심혈관질환, 고혈압, 고지혈증 같은 심각한 성인병을 유발할 수 있으며, 각종 암의 유병률을 높이기 때문에 치료에 많은 관심이 모이고 있다.Obesity, as well as its own problems, can cause serious adult diseases such as diabetes, cardiovascular disease, high blood pressure, and hyperlipidemia, and since it increases the prevalence of various cancers, there is a lot of interest in treatment.
세계보건기구(WHO) 2014년의 통계에 따르면 전 세계적으로 18세 이상의 성인 중 19억이 과체중이며 그중 6억이 비만에 도달하였다. 비만은 심혈관계 질환, 제 2형 당뇨병 및 여러 유형의 암 발생 빈도를 증가시키는 주요 요인 중 하나로, 매년 280만 명 이상이 과체중이나 비만으로 인해 사망하고 있다. According to statistics from the World Health Organization (WHO) 2014, worldwide 1.9 billion of adults over the age of 18 are overweight, of which 600 million have reached obesity. Obesity is one of the main factors that increase the incidence of cardiovascular disease,
또한, 현대인들의 생활수준이 향상되면서 지난 10년간 우리나라 사람들의 지방 섭취량은 5.9g 증가하여 비만 유병률은 2005년 대비 1.9% 증가한 것으로 조사되었다. 특히, 남자 비만 유병률은 39.7%까지 크게 증가하였으며 고 콜레스테롤혈증 유병률이 17.9%로 9.9% 증가하고 있어 비만은 치료해야 할 질병으로 인식하여 세계적인 영양문제로 다루고 있다.In addition, as the living standards of modern people improved, the fat intake of Koreans in the past 10 years increased by 5.9g, and the prevalence of obesity increased by 1.9% compared to 2005. In particular, the prevalence of obesity in males has increased significantly to 39.7%, and the prevalence of hypercholesterolemia is increasing by 9.9% to 17.9%. Obesity is recognized as a disease to be treated and is treated as a global nutritional problem.
비만을 개선하기 위한 방법으로는 외과적 치료 외에 운동요법, 식사요법, 행동요법 그리고 식용 억제제, 설사제 또는 포만감을 주기 위한 섬유질 등을 사용하는 약물요법 등이 현재 알려져 있다. 최근에는 비만 치료를 위한 약물 치료제 개발 연구가 진행되고 있지만, 현재까지 개발된 약물치료제는 효능에 비해 두통, 불면증, 신경불안, 고혈압, 복통, 복부팽만, 배변 증가 등의 부작용이 있는 것으로 알려져 있다.As a method for improving obesity, in addition to surgical treatment, exercise therapy, diet therapy, behavior therapy, and drug therapy using dietary inhibitors, laxatives or fiber to give a feeling of fullness are currently known. In recent years, research on drug therapy development for the treatment of obesity is in progress, but the drug therapy developed so far is known to have side effects such as headache, insomnia, nervous anxiety, high blood pressure, abdominal pain, abdominal distention, and increased bowel movement compared to its efficacy.
약물 치료는 크게 작용기전에 따라 식욕억제제와 지방흡수 억제제로 나누어진다. 그러나 식욕을 억제하는 시부트라민(sibutramine) 은 심혈관계 부작용이 있고, 펜터민(Phentermine)과 디에틸프로피온(Diethylpropion)등의 약물 들은 혈압 상승, 어지럼증, 두통, 진전, 구갈 등의 부작용이 있다. 지방흡수 억제제인 올리스타트(orlistat)의 경우 지방에 용해되는 비타민의 흡수가 억제되고 지방변, 지방배출, 빈번한 배변, 대변 실금이 있을 수 있다.Drug treatment is largely divided into appetite suppressants and fat absorption inhibitors depending on the mechanism of action. However, sibutramine, which suppresses appetite, has side effects on the cardiovascular system, and drugs such as phentermine and diethylpropion have side effects such as increased blood pressure, dizziness, headache, tremors, and dry mouth. In the case of orlistat, a liposuction inhibitor, absorption of vitamins dissolved in fat is suppressed, and there may be fat stool, fat excretion, frequent bowel movements, and stool incontinence.
이러한 약물 치료의 부작용으로 인해 새로운 항비만 기능성 식품 및 의약품 개발이 요구되고 있으며, 최근에는 천연물소재에서 비만 예방 및 개선에 효과적인 기능성 소재들을 찾아내고 작용 기전을 밝히는 연구 및 개발이 이루어지고 있다.Due to the side effects of such drug treatment, the development of new anti-obesity functional foods and pharmaceuticals is required, and in recent years, research and development to find functional materials effective in preventing and improving obesity from natural materials and revealing the mechanism of action have been conducted.
천연 기능성 소재의 개발은 항비만 효능과 연계하여 의약품 혹은 다이어트 식품류 등으로 보다 안전하고 우수한 효능의 제품 개발이 가능할 것으로 사료되며, 그 효능을 과학적으로 검증하고자 하였다.The development of natural functional materials is considered to be possible to develop safer and more effective products such as pharmaceuticals or diet foods in connection with anti-obesity efficacy, and its efficacy was to be scientifically verified.
본 발명의 목적은 천연 추출물을 포함하는 비만 개선 및 치료용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for treating and improving obesity comprising a natural extract.
본 발명의 다른 목적은 지방세포분화와 관련된 전사인자의 발현을 조절함으로써 체중 및 체지방 감소와 혀중 지질 수치 개선 효능이 우수한 비만 치료 및 개선용 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for treating and improving obesity having excellent efficacy in reducing weight and body fat and improving lipid levels in the tongue by controlling the expression of transcription factors related to adipocyte differentiation.
본 발명의 다른 목적은 부작용의 문제가 없으며, 비자극성으로 비만 개선 및 치료 효과가 우수한 약학 조성물, 기능성 식품 및 차(茶)를 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition, functional food, and tea with no side effects, and excellent anti-obesity improvement and treatment effects due to non-irritating properties.
상기 목적을 달성하기 위하여, 본 발명의 일 실시예에 따른 비만 치료 및 개선용 조성물은 일년봉(Erigeron annuus (L.) Pers) 추출물 및 보리지(Borage officinalis) 추출물을 유효 성분으로 포함하며,In order to achieve the above object, the composition for the treatment and improvement of obesity according to an embodiment of the present invention includes an extract of Erigeron annuus (L.) Pers and an extract of Borage officinalis as an active ingredient,
낭아초 (Indigofera pseudotinctoria) 추출물, 수호초 (Pachysandra terminalis) 추출물, 비비추 (Hosta longipes) 및 이들의 혼합물로 이루어진 군으로부터 선택되는 천연 추출물을 추가로 포함하는 것이다.It further comprises a natural extract selected from the group consisting of cystweed (Indigofera pseudotinctoria) extract, pachysandra terminalis extract, bibichu (Hosta longipes) and mixtures thereof.
상기 조성물은 PPARγ와 C/EBPα의 발현을 억제하여, 항비만 효과가 우수한 것이다.The composition inhibits the expression of PPARγ and C/EBPα, and has excellent anti-obesity effect.
상기 추출물은 물, C₁ 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출하는 것을 포함한다.The extract includes extraction using an extraction solvent selected from the group consisting of water, C₁ to C6 lower alcohols, and mixtures thereof.
본 발명의 다른 일 실시예에 따른 약학 조성물은 상기 비만 치료 및 개선용 조성물을 포함할 수 있다.The pharmaceutical composition according to another embodiment of the present invention may include the composition for treating and improving obesity.
본 발명의 다른 일 실시예에 따른 기능성 식품은 상기 비만 치료 및 개선용 조성물을 포함할 수 있다.Functional food according to another embodiment of the present invention may include a composition for treating and improving obesity.
본 발명의 다른 일 실시예에 따른 차(茶)는 상기 비만 치료 및 개선용 조성물을 포함할 수 있다.Tea according to another embodiment of the present invention may include the composition for treating and improving obesity.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 명세서에서 사용되는 용어 '추출물'은 상술한 바와 같이 당엽계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 추출물에 포함되는 것이다.The term'extract' as used herein has the meaning commonly used as a crude extract in the sugar leaf system as described above, but broadly includes a fraction obtained by additionally fractionating the extract. That is, the extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, fractions obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the purification method are also included in the extract of the present invention.
본 발명에서 이용되는 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The extract used in the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze drying or spray drying.
본 발명의 일 실시예에 따른 비만 치료 및 개선용 조성물은 일년봉(Erigeron annuus (L.) Pers) 추출물 및 보리지(Borage officinalis) 추출물을 유효 성분으로 포함하며,The composition for the treatment and improvement of obesity according to an embodiment of the present invention includes an extract of Erigeron annuus (L.) Pers and an extract of Borage officinalis as an active ingredient,
낭아초 (Indigofera pseudotinctoria) 추출물, 수호초 (Pachysandra terminalis) 추출물, 비비추 (Hosta longipes) 및 이들의 혼합물로 이루어진 군으로부터 선택되는 천연 추출물을 추가로 포함하는 것이다.It further comprises a natural extract selected from the group consisting of cystweed (Indigofera pseudotinctoria) extract, pachysandra terminalis extract, bibichu (Hosta longipes) and mixtures thereof.
일년봉(Erigeron annuus (L.) Pers)은 북아메리카 원상으로, 우리나라 각처의 밭, 들, 길가에 나는 월년초로 국화 속 식물이며 소화불량, 학질, 장염, 간염, 이뇨작용이나 혈당 강하 작용 등 여러 가지 생리 활성이 알려져 있다.Erigeron annuus (L.) Pers is native to North America. It is a plant in the genus of chrysanthemum that grows in fields, fields, and roadsides in various parts of Korea. Eggplant physiological activity is known.
보리지(Borage officinalis)는 월년초로 원산지는 지중해 연안이며 고대 그리스나 로마시대부터 즐겨 이용한 허브로 꽃이나 잎을 술에 담갔다가 마시면 모든 슬픔이나 시름을 씻어 주어 기분을 즐겁고 명랑하게 해준다 하여 “쾌활초 (cuphorosium)”라고 불렸다. 전통의학에서는 보리지를 과민성 위장질환, 호흡기 및 심혈관계 질환에 사용하여 복통, 설사, 천식, 기관지염, 고혈압, 방광염 등을 치료하기 위한 약초로 알려져 있다.Borage officinalis is the beginning of the month and its origin is the Mediterranean coast. It is a herb that has been used since ancient Greek and Roman times. If you drink flowers or leaves in alcohol, it will wash away all sorrows and annoyances, making you feel pleasant and cheerful. It was called “cuphorosium”. In traditional medicine, borage is known as a medicinal herb for treating abdominal pain, diarrhea, asthma, bronchitis, high blood pressure, cystitis, etc. by using borage for irritable gastrointestinal diseases, respiratory and cardiovascular diseases.
낭아초(Indigofera pseudotinctoria)는 낙엽 활엽반관목으로, 가지를 많이 쳐서 옆으로 자라며, 작은 가지에는 북모가 있고 가늘다. 높이는 2m 정도이다. 잎은 작은 잎이 5 내지 11개이고, 타원상 도란형, 타원형 또는 긴 타원형이며, 잎자루는 1 내지 3cm인, 홀수깃꼴겹잎이다. 가장 자리는 밋밋하고 잎끝이 둔하거나 오목하고, 잎밑은 둥글다. 뿌리 부위는 약용으로 쓰인다.Cygnus (Indigofera pseudotinctoria) is a deciduous broad-leaved semi-shrub, which grows sideways by striking a lot of branches, and small branches have a north hair and are thin. The height is about 2m. Leaves are 5 to 11 small leaves, oval obovate, oval or long oval, petiole is 1 to 3 cm, odd pinnate compound leaves. The edge is flat and the tip of the leaf is dull or concave, and the bottom of the leaf is round. The root area is used for medicinal purposes.
수호초(Pachysandra terminalis)는 나무 그늘에서 자라며 원줄기가 옆으로 벋으면서 끝이 곧추서고 녹색이며 처음에는 잔 털이 있으나 점차 없어진다. 높이 30cm 내외로 자란다. 잎은 어긋나지만 윗부분에 모여 달리고 달걀을 거꾸로 세운 듯한 모양이며 윗부분에 톱니가 있다. 잎 표면 맥 위에 잔털이 있고 밑부분이 좁아져 잎자루가 된다. 또한 꽃은 4 또는 5월에 피고 흰색이며 수상꽃차례에 달린다. 암꽃은 꽃이삭 밑부분에 약간 달리고 수꽃은 윗부분에 많이 달린다. 꽃받침은 4개로 갈라지고 꽃잎은 없다. 수술은 3 내지 5개이고 암술대는 2개로 갈라져서 젖혀진다. 열매는 핵과로서 달걀 모양이고 겉에 털이 없다. 한국, 일본, 사할린섬, 중국에 분포한다.Pachysandra terminalis grows in the shade of a tree, and its main stem is sideways and its end is upright and green. At first, it has fine hairs but gradually disappears. It grows around 30cm in height. The leaves are alternate, but they run together on the upper part, and the egg looks like it is upside down, and there are serrations on the upper part. There are fine hairs on the veins on the leaf surface, and the lower part becomes narrow to become a petiole. Also, flowers bloom in April or May, are white, and hang on water inflorescences. Female flowers hang slightly at the bottom of the flower head, and male flowers hang at the top. The calyx is divided into 4 and there are no petals. The number of stamens is 3 to 5, and the style is split into two and turned over. The fruit is a drupe, egg-shaped and hairless on the outside. It is distributed in Korea, Japan, Sakhalin Island, and China.
비비추(Hosta longipes)는 산지의 냇가나 습기가 많은 곳에서 잘 자라며 높이 30 내지 40cm이다. 잎은 모두 뿌리에서 돋아서 비스듬히 자란다. 잎은 타원형이며 끝이 뾰족하고 8 또는 9맥이 있다. 꽃은 연한 자줏빛으로 7 또는 8월에 피고 한쪽으로 치우쳐서 총상으로 달리며 꽃줄기는 길이 30 내지 40cm이다. 포는 얇은 막질이고 자줏빛이 도는 흰색이며 작은꽃자루의 길이와 거의 비슷하다. 화관은 끝이 6개로 갈라져서 갈래조각이 약간 뒤로 젖혀지고 6개의 수술과 1개의 암술이 길게 꽃 밖으로 나온다. 열매는 삭과로 긴 타원형이다. 종자는 검은색으로서 가장자리에 날개가 있다. 연한 순을 식용하며 관상용으로 심는다. 야생종은 한국·일본·중국 등지에 분포한다. 비비추는 원예종으로 다양한 품종이 개발되어 외국에서 정원식물로 인기가 높다.Hosta longipes grow well in mountain streams or in humid places, with a height of 30 to 40 cm. All leaves sprout from the roots and grow at an angle. The leaves are oval, the ends are sharp, and there are 8 or 9 veins. Flowers are pale purple, bloom in July or August, lean to one side and hang as a raceme, and the stalk is 30 to 40cm long. The bract is thin, purplish white, almost the same length as the peduncle. The end of the corolla is split into 6 pieces, and the forked piece is slightly bent back, and 6 stamens and 1 pistil are long out of the flower. Fruit is capsule, long oval. The seeds are black and have wings at the edges. Light sprouts are edible and planted for ornamental purposes. Wild species are distributed in Korea, Japan, and China. Bibichu is a horticultural species, and various varieties have been developed and are popular as garden plants in foreign countries.
보다 바람직하게 본 발명의 항비만용 조성물은 일년봉 추출물 100중량부에 대하여, 보리지 추출물 80 내지 100 중량부, 낭아초 추출물 20 내지 40 중량부, 수호초 추출물 20 내지 40 중량부 및 비비추 추출물 20 내지 40 중량부로 포함할 수 있다.More preferably, the composition for anti-obesity of the present invention is based on 100 parts by weight of an annual stick extract, 80 to 100 parts by weight of borage extract, 20 to 40 parts by weight of cystweed extract, 20 to 40 parts by weight of sukhocho extract, and 20 to 40 parts by weight of bibichu extract It may contain 40 parts by weight.
상기 범위에 의하는 경우, 우수한 체중 및 체지방 감소, 혈중 지질 수치를 개선하는 효과를 나타낼 수 있다.In the case of the above range, it may exhibit excellent weight and body fat reduction, and an effect of improving blood lipid levels.
상기 본 발명의 비만 치료 및 개선용 조성물을 기능성 식품 조성물 및 차(茶)로 제공하는 경우, 천연 추출물의 고유의 향과 맛이 그대로 전달되어, 기호성이 낮은 문제가 있다.In the case of providing the composition for treating and improving obesity of the present invention as a functional food composition and tea, the inherent aroma and taste of the natural extract is transmitted as it is, and there is a problem of low palatability.
이러한 문제를 방지하기 위해, 화학조미료를 이용하는 방법도 고려될 수 있으나, 화학 조미료를 이용하는 것은, 본 발명에서 부작용이 없는 천연 조성물로 기능성 식품 조성물 및 차(茶)를 제공하는 취지에 부합하지 않는 점을 고려할 , 바람직하지 않은 문제가 있다.In order to prevent this problem, a method of using a chemical seasoning may also be considered, but the use of a chemical seasoning does not conform to the purpose of providing a functional food composition and tea with a natural composition without side effects in the present invention. ‹Š to consider, there is an undesirable problem.
이러한 문제를 방지하기 위해, 보다 바람직하게 본 발명에서는 기호성을 향상시키기 위해, 삼백초(Saururus chinensis (Lour.) Baill.) 추출물 및 나한과(Siraitia grosvenorii) 추출물을 추가로 포함할 수 있다.In order to prevent this problem, more preferably, in the present invention, in order to improve palatability, it may further include an extract of Saururus chinensis (Lour.) Baill. and an extract of Siraitia grosvenorii.
상기 삼백초(Saururus chinensis (Lour.) Baill.)는 습지에 자라는 다년초로 높이 50 내지 100cm이며 근경은 백색이다. 잎은 호생하며 끝이 뾰족하고 밑부분은 심장상 이저이고 가장자리가 밋밋하다. 꽃은 양성으로서 6 내지 8월에 백색으로 피고 수상화서는 잎과 대생한다. 열매는 둥글고 3 내지 5실로 되어 있으며, 종자는 각 실에 1개씩 들어 있다.Saururus chinensis (Lour.) Baill. is a perennial plant growing in wetlands and has a height of 50 to 100 cm and a rhizome of white. The leaves grow alternately, the ends are sharp, the bottom is heart-shaped, and the edges are flat. The flower is benign, blooms white in June to August, and the water inflorescence is opposite to the leaf. Fruits are round and consist of 3 to 5 threads, with 1 seed in each thread.
상기 나한과(Siraitia grosvenorii)는 조롱박과의 초본 다년생 식물이며 중국 및 태국 등지에 자생한다. 나한과의 열매와 잎은 한방에서 약 재로 사용하는데, 주로 고랭지에서 자생하며 안개가 많고 서늘한 기후와 햇볕을 좋아하고 배수가 잘되며 부식질 이 많은 토양에서 서식하므로 재배조건이 까다로워 인위적인 재배가 어려운 식물로 예로부터 귀한 약재로 사용되어 왔다.The Siraitia grosvenorii is a herbaceous perennial plant of the gourd family and grows wild in China and Thailand. The fruits and leaves of the Nahan family are used as medicinal materials in oriental medicine.It is a plant that is difficult to artificially cultivate due to difficult cultivation conditions because it grows naturally in highlands, likes a cool climate, sunlight, drains well, and lives in a lot of humus. It has been used as a valuable medicine since ancient times.
상기 삼백초 추출물 및 나한과 추출물을 추가로 포함함에 따라, 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물만을 사용하는 경우에 비해, 항비만 효과는 높이며, 기호성이 우사한 기능성 식품 조성물로의 제공을 가능하게 한다.By additionally including the Sambaekcho extract and Nahan fruit extract, compared to the case of using only an annual bong extract, borage extract, cystic vinegar extract, sukhoweed extract and bibichu extract, the anti-obesity effect is increased, and the functional food has superior palatability. It makes it possible to provide a composition.
보다 바람직하게 상기 비만 치료 및 개선용 조성물은 일년봉 추출물 100중량부에 대하여, 보리지 추출물 80 내지 100 중량부, 낭아초 추출물 20 내지 40 중량부, 수호초 추출물 20 내지 40 중량부, 비비추 추출물 20 내지 40 중량부, 삼백초 추출물 5 내지 10 중량부 및 나한과 추출물 5 내지 10 중량부로 포함할 수 있다.More preferably, the composition for the treatment and improvement of obesity is based on 100 parts by weight of an annual bong extract, 80 to 100 parts by weight of borage extract, 20 to 40 parts by weight of cystic vinegar extract, 20 to 40 parts by weight of Suhocho extract, 20 to 20 parts by weight of bibichu extract It may contain 40 parts by weight, 5 to 10 parts by weight of Sambaekcho extract, and 5 to 10 parts by weight of Nahan fruit extract.
상기 수치 범위 내에서의 사용에 의하는 경우, 각 구성 성분 간의 혼합 사용에 따른 복합 작용으로 인해, 기호성이 우수한 기능성 식품 및 차(茶)를 제공할 수 있다.In the case of use within the above numerical range, functional foods and tea having excellent palatability can be provided due to the complex action resulting from the mixed use of each component.
상기 조성물은 PPARγ와 C/EBPα의 발현을 억제하여, 항비만 효과가 우수한 것이다.The composition inhibits the expression of PPARγ and C/EBPα, and has excellent anti-obesity effect.
상기 PPARγ(Peroxisome proliferator activated receptor γ)와 C/EBPα (CCAAT-enhancer-binding protein α)는 지방세포 형성 과정에 관여하는 중요한 인자로, PPARγ는 retinoid X receptor(RXR)와 헤테로다이머(heterodimer)를 형성하여 표적유전자의 발현을 조절하는 전사인자이다. The PPARγ (Peroxisome proliferator activated receptor γ) and C/EBPα (CCAAT-enhancer-binding protein α) are important factors involved in the process of adipocyte formation, and PPARγ forms retinoid X receptor (RXR) and heterodimer. It is a transcription factor that regulates the expression of the target gene.
이들 두 인자는 분화 초기에 발현되는 C/EBPs에 의해 유전자 발현이 증가하고 지방세포가 분화되는 동안 아디포넥틴(adiponectin)과 GLUT4(glucose transporter 4)와 같은 지방생성 유전자(adipogenic gene)의 발현을 조절한다.These two factors increase gene expression by C/EBPs expressed in the early stages of differentiation and regulate the expression of adipogenic genes such as adiponectin and GLUT4 (glucose transporter 4) during adipocyte differentiation. .
이에 상기 조성물은 PPARγ와 C/EBPα의 발현을 억제함으로써, 우수한 체중 및 체지방 감소, 혈중 지질 수치를 개선하는 효과를 나타낼 수 있다.Accordingly, the composition may exhibit excellent weight and body fat reduction and improved blood lipid levels by inhibiting the expression of PPARγ and C/EBPα.
상기 추출물은 물, C₁ 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출하는 것을 포함한다.The extract includes extraction using an extraction solvent selected from the group consisting of water, C₁ to C6 lower alcohols, and mixtures thereof.
구체적으로, 상기 천연 추출물을 제조하기 위해서는 천연물을 분쇄하는 단계; 유기 용매를 사용하여 상기 분쇄물을 침출시키는 단계; 시료를 침출 후 건조시키는 단계; 건조된 시료를 유기 용매를 사용하여 재 침출 시키는 단계; 시료를 침출 후 건조시키는 단계; 물을 이용하여 침출시키는 단계; 및 침출하는 단계를 포함하여, 천연 추출물을 획득할 수 있다.Specifically, in order to prepare the natural extract, pulverizing the natural product; Leaching the pulverized product using an organic solvent; Drying the sample after leaching; Re-leaching the dried sample using an organic solvent; Drying the sample after leaching; Leaching with water; And including the step of leaching, it is possible to obtain a natural extract.
상기 유기 용매를 사용하여 추출한 천연 추출물은 유기 용매를 사용하여 분획을 실시하는 단계를 더 포함할 수 있다.The natural extract extracted using the organic solvent may further include performing fractionation using an organic solvent.
상기 추출물을 제조하는 방법은 초음파 추출법, 침출법 및 환류 추출법 등 당업계의 통상적인 추출 방법일 수 있다. 구체적으로 세척 및 건조로 이물질이 제거된 천연물을 물, 탄소수 1내지 6의 알코올 또는 이들의 혼합 용매로 추출한 추출물일 수 있으며, 상기 용매들을 순차적으로 시료에 적용하여 추출한 추출물일 수 있다.The method of preparing the extract may be a conventional extraction method in the art, such as an ultrasonic extraction method, a leaching method, and a reflux extraction method. Specifically, it may be an extract obtained by extracting a natural product from which foreign substances are removed by washing and drying with water, alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof, and the extract may be extracted by sequentially applying the solvents to a sample.
상기 환류 추출법은 물, 탄소수 1 내지 6의 알코올 100mL기준으로, 천연물의 분쇄물 10 내지 30g, 환류 시간 1 내지 3시간 및 50 내지 100%의 탄소수 1 내지 6의 알코올 또는 물에 의한다. 보다 구체적으로, 탄소수 1 내지 6의 알코올 100Ml 또는 물 100mL 기준으로, 천연물의 분쇄물 10 내지 20g, 환류 시간 1 내지 2시간 및 70 내지 90%의 탄소수 1 내지 4의 알코올 또는 물에 의한 것이다.The reflux extraction method is based on 100 mL of water and an alcohol having 1 to 6 carbon atoms, using 10 to 30 g of a pulverized product of a natural product, a reflux time of 1 to 3 hours, and an alcohol or water having 1 to 6 carbon atoms of 50 to 100%. More specifically, based on 100Ml of alcohol having 1 to 6 carbon atoms or 100 mL of water, 10 to 20 g of a pulverized product of a natural product, a reflux time of 1 to 2 hours, and 70 to 90% of an alcohol or water having 1 to 4 carbon atoms.
상기 침출법은 15 내지 30℃, 24 내지 72시간 동안 진행하며, 추출 용매로 물 또는 50 내지 100%의 탄소수 1 내지 6의 알코올을 이용한다. 보다 구체적으로는 20 내지 25℃, 30 내지 54시간 동안 진행하며, 추출 용매는 물 또는 70 내지 80%의 탄소수 1 내지 6의 알코올에 의한 것이다.The leaching method is performed at 15 to 30° C. for 24 to 72 hours, and water or 50 to 100% alcohol having 1 to 6 carbon atoms is used as an extraction solvent. More specifically, it proceeds for 20 to 25° C. for 30 to 54 hours, and the extraction solvent is made of water or an alcohol having 1 to 6 carbon atoms of 70 to 80%.
상기 초음파 추출법은 30 내지 50℃, 0.5 내지 2.5시간 동안 반응을 진행하며, 추출용매는 물 또는 50 내지 100%의 탄소수 1 내지 6의 알코올에 의한 것이다. 구체적으로는 40 내지 50℃, 1 내지 2.5시간 동안 추출하며, 추출용매로 물 또는 70 내지 80%의 탄소수 1 내지 6의 알코올에 의한 것이다.The ultrasonic extraction method proceeds for a reaction at 30 to 50° C. for 0.5 to 2.5 hours, and the extraction solvent is water or an alcohol having 1 to 6 carbon atoms of 50 to 100%. Specifically, extraction is performed at 40 to 50° C. for 1 to 2.5 hours, and water or an alcohol having 1 to 6 carbon atoms of 70 to 80% is used as an extraction solvent.
상기 추출 용매는 시료의 중량 기준으로 2 내지 50배를 사용할 수 있으며, 보다 구체적으로는 2 내지 20배이다. 추출을 위해 시료는 추출 용매에서 침출을 위해 1 내지 72 시간 동안 방치될 수 있으며, 보다 구체적으로 24 내지 48시간 동안 방치될 수 있다.The extraction solvent may be 2 to 50 times the weight of the sample, and more specifically 2 to 20 times. For extraction, the sample may be left for 1 to 72 hours for leaching in the extraction solvent, and more specifically, for 24 to 48 hours.
추출 후, 추출물은 새로운 분획 용매를 순차적으로 적용하여 분획할 수 있다. 분획시 사용하는 분획 용매는 상기 용매는 물, 헥산, 부탄올, 에틸아세트산, 에틸 아세테이트, 메틸렌클로라이드 및 이들의 혼합물로 이루어진 군으로부터 선택된 어느 하나 이상이며, 바람직하게는 에틸아세테이트 또는 메틸렌클로라이드이다.After extraction, the extract can be fractionated by sequentially applying a new fractionation solvent. The fractionation solvent used for fractionation is at least one selected from the group consisting of water, hexane, butanol, ethyl acetic acid, ethyl acetate, methylene chloride, and mixtures thereof, and preferably ethyl acetate or methylene chloride.
추출물 또는 분획물을 얻은 후에는 농축 또는 동결건조 등의 방법을 추가적으로 사용할 수 있다.After obtaining the extract or fraction, a method such as concentration or lyophilization may be additionally used.
본 발명의 다른 일 실시예에 따른 약학 조성물은 상기 비만 치료 및 개선용 조성물을 포함할 수 있다.The pharmaceutical composition according to another embodiment of the present invention may include the composition for treating and improving obesity.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 추출물은 1일 0.01 mg/kg 내지 10 g/kg으로, 바람직하게는 1 mg/kg 내지 1 g/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 그러므로 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the extract of the present invention varies depending on the condition and weight of the patient, the degree of disease, the form of the drug, the route and duration of administration, but may be appropriately selected by those skilled in the art. However, for a desirable effect, the extract is preferably administered at 0.01 mg/kg to 10 g/kg per day, preferably 1 mg/kg to 1 g/kg. Administration may be administered once a day, or may be divided several times. Therefore, the dosage does not limit the scope of the present invention in any way.
본 발명의 다른 일 실시예에 따른 기능성 식품은 상기 비만 치료 및 개선용 조성물을 포함할 수 있다.Functional food according to another embodiment of the present invention may include a composition for treating and improving obesity.
본원에서 정의되는 "기능성 식품"은 기능성 식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다."Functional food" as defined herein refers to a food manufactured and processed using raw materials or ingredients that have functions useful for the human body according to the Functional Food Act No.6727, and "functional" refers to the structure of the human body and It refers to ingestion for the purpose of obtaining useful effects for health purposes such as controlling nutrients for function or physiological action.
본 발명의 다른 일 실시예에 따른 차(茶)는 상기 비만 치료 및 개선용 조성물을 포함할 수 있다.Tea according to another embodiment of the present invention may include the composition for treating and improving obesity.
본 발명의 비만 치료 및 개선용 조성물에 의하면 지방세포분화와 관련된 전사인자의 발현을 조절함으로써 체중과 체지방을 감소하며, 혈중 지질 수치 개선효과가 우수하다.According to the composition for treating and improving obesity of the present invention, weight and body fat are reduced by controlling the expression of transcription factors related to adipocyte differentiation, and the effect of improving blood lipid levels is excellent.
또한, 부작용이 없으며, 비자극성인 천연 추출물을 유효성분으로 포함하는 비만 치료 및 개선용 조성물을 포함하는 약학 조성물, 기능석 식품 및 차(茶)로 제공할 수 있다.In addition, it can be provided as a pharmaceutical composition including a composition for treating and improving obesity, including a non-irritating natural extract as an active ingredient, functional stone food, and tea.
도 1은 C57BL/6J 마우스에서 일년봉과 보리지 추출물 그리고 이들의 추출 혼합물을 투여했을 때 8주 동안의 체중 변화를 나타낸 것이다.
도 2은 일년봉과 보리지 추출물 그리고 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물을 투여했을 때 부고환 지방 조직에서 지방 생성에 관여하는 단백질의 발현 정도를 나타낸 것이다.
도 3은 PPARγ의 발현 정도를 그래프로 나타낸 것이다.
도 4는 C/EBPα의 발현 정도를 그래프로 나타낸 것이다.
도 5는 Adipoenctin의 발현 정도를 그래프로 나타낸 것이다.Figure 1 shows the change in body weight for 8 weeks when administering an annual stick and borage extract and an extract mixture thereof in C57BL/6J mice.
Figure 2 shows the expression level of a protein involved in adipogenesis in the epididymal adipose tissue when a mixture of an annual bark and borage extract and an annual bark extract, borage extract, cystoid extract, suhocho extract and bibichu extract is administered.
3 is a graph showing the expression level of PPARγ.
4 is a graph showing the expression level of C/EBPα.
5 is a graph showing the expression level of Adipoenctin.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be implemented in various different forms and is not limited to the embodiments described herein.
[제조예: 추출물의 제조][Production Example: Preparation of extract]
1. 일년봉 추출물 제조1. Manufacture of annual extract
일년봉 시료에 추출 용매인 50% 에탄올을 1:10(w:v)의 비율로 가한 다음 완전히 침지 시킨 후, 80℃에서 환류시키면서 3시간씩 3회 반복 추출하였다. 추출액은 Whatman No. 2 여과지로 여과하였다. 여과액은 60℃에서 감압 농축하여 일년봉 추출물(E1)을 제조하였다.50% ethanol, an extraction solvent, was added to the annual sample at a ratio of 1:10 (w:v), and then completely immersed, followed by
2. 보리지 추출물 제조2. Preparation of borage extract
보리지 시료에 추출 용매인 증류수를 1:10(w:v)의 비율로 가한 다음 충분히 침지 시킨 후, 80℃에서 3시간씩 3회 반복 추출하였다. 추출액은 Whatman No. 2 여과지로 여과하였다. 여과액은 60℃에서 감압 농축하여 보리지 추출물(B1) 제조하였다.Distilled water, which is an extraction solvent, was added to the borage sample at a ratio of 1:10 (w:v) and then sufficiently immersed, followed by extraction three times at 80°C for 3 hours each. Whatman No. 2 Filtered with filter paper. The filtrate was concentrated under reduced pressure at 60° C. to prepare a borage extract (B1).
3. 기타 천연 추출물 제조3. Manufacture of other natural extracts
상기 일년봉 추출물(E)의 제조 방법과 동일한 방법을 이용하여, 낭아초 추출물(I), 수호초 추출물(P), 비비추 추출물(H), 삼백초 추출물(S) 및 나한과 추출물(G)을 제조하였다.Using the same method as the production method of the annual bong extract (E), cystic vinegar extract (I), Suhocho extract (P), Bibichu extract (H), Sambaekcho extract (S) and Nahan fruit extract (G) were prepared I did.
4. 복합 추출물의 제조4. Preparation of complex extract
상기 일년봉 추출물(E), 보리지 추출물(B), 낭아초 추출물(I), 수호초 추출물(P), 비비추 추출물(H), 삼백초 추출물(S) 및 나한과 추출물(G)을 하기 표 1과 같이 혼합하여 복합 추출물로 제조하였다.The annual extract (E), borage extract (B), cystocarp extract (I), suhocho extract (P), bibichu extract (H), sambaekcho extract (S) and nahan fruit extract (G) are shown in Table 1 below. By mixing as described above, it was prepared as a complex extract.
(단위: 중량부)(Unit: parts by weight)
[실험예1: 비만 치료 및 개선 효과에 대한 평가][Experimental Example 1: Evaluation of Obesity Treatment and Improvement Effect]
1. 실험동물 및 비만 유도1. Experimental animals and obesity induction
특정 병원체 (specific pathogen free)가 없는 5주 령의 C57BL/6J 마우스를 ㈜중앙실험동물(Central Lab-Animal Inc., Seoul, Korea)에서 구입하여 1주일간 사육실에서 적응시킨 후 실험에 사용하였다. 동물 사육실의 온도 및 습도는 24±5℃, 55±5%로 설정하였으며 lighting cycle은 12시간 주기로 하였다.A 5-week-old C57BL/6J mouse without specific pathogen free was purchased from Central Lab-Animal Inc., Seoul, Korea, and was acclimated in a breeding room for 1 week and used for the experiment. The temperature and humidity of the animal breeding room were set to 24±5℃ and 55±5%, and the lighting cycle was set to a 12-hour cycle.
실험 군으로는 정상식이군(Normal Fat)에게 총 칼로리의 10%가 지방인 일반 식이(NF; 10% kcal fat; Research Diet, Inc., No. D12450B)를 공급하였고 고지방식이군(High Fat)에는 비만 유도를 위하여 총 칼로리의 60%가 지방인 고지방식이(HF; 60% kcal fat; Research Diet, Inc., No. D12492)를 공급하여 비만 유도를 3주간 진행하였다.As the experimental group, a normal diet (NF; 10% kcal fat; Research Diet, Inc., No. D12450B), in which 10% of total calories are fat, was supplied to the normal diet group (Normal Fat), and to the high fat diet group (High Fat). In order to induce obesity, a high-fat diet (HF; 60% kcal fat; Research Diet, Inc., No. D12492) in which 60% of total calories are fat was supplied to induce obesity for 3 weeks.
비만 유도 후 실험동물은 난괴법으로 정상식이군(NF; n=6), 고지방식이군(HF; n=6), 양성대조군은 고지방식에 가르시니아 캄보지아 추출물 100 mg/kg/day 투여한군(HF+G100; n=6), 추출물 투여 군으로 고지방식에 일년봉 추출물(이하 'E'라 함) 100 mg/kg/day 투여한군(HF+E100; n=6), 고지방식이에 E 200 mg/kg/day 투여한군(HF+E200; n=6), 고지방식이에 보리지 추출물(이하 'B'라 함) 100 mg/kg/day 투여한 군(HF+B100; n=6), 고지방식이에 B 200 mg/kg/day 투여한 군(HF+B200; n=6), 고지방식이에 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물(이하 'TE'라 함) 100 mg/kg/day 투여한 군(HF+TE100; n=6), 고지방식이에 TE 200 mg/kg/day 투여한 군(HF+TE200; n=6)으로 총 9군으로 분류하여 모든 추출물을 증류수에 용해하여 8주간 경구투여를 실시하였다.After induction of obesity, the experimental animals were treated with egg mass method in the normal diet group (NF; n=6), high fat diet group (HF; n=6), and the positive control group administered garcinia cambogia extract 100 mg/kg/day on a high fat diet (HF+ G100; n=6), group administered with 100 mg/kg/day of annual extract (hereinafter referred to as'E') on a high fat diet (HF+E100; n=6), 200 mg of E on a high fat diet /kg/day administration group (HF+E200; n=6), high fat diet with borage extract (hereinafter referred to as'B') 100 mg/kg/day administration group (HF+B100; n=6), Group administered B 200 mg/kg/day on a high fat diet (HF+B200; n=6), a mixture of annual bong extract, borage extract, cystweed extract, sukhoweed extract and bibichu extract (hereinafter referred to as' TE') 100 mg/kg/day administered group (HF+TE100; n=6), high fat diet group administered TE 200 mg/kg/day (HF+TE200; n=6), total 9 Classified into groups, all extracts were dissolved in distilled water and administered orally for 8 weeks.
2. 체중 및 식이 급여2. Weight and dietary salary
본 실시 예에 실험동물이 자유롭게 물과 식이를 섭취하도록 하였고, 주 1회 체중을 측정하였으며(도 1), 매주 동일한 시간에 식이를 공급하여 전주에 남은 식이량과 그날 공급한 식이량의 차이로 섭취 식이량을 계산하였다.In this example, the experimental animals were allowed to freely consume water and diet, and the body weight was measured once a week (Fig. 1), and the diet was supplied at the same time each week, and the difference between the amount of diet remaining in the previous week and the amount of diet supplied that day The intake diet amount was calculated.
Group
Group
weight
(g)Initial body
weight
(g)
(g)Final body weight
(g)
(g)Body weight gain
(g)
intake
(g/day)Food
intake
(g/day)
(g/day)Water intake
(g/day)
(Kcal/day)Energy intake
(Kcal/day)
(%)Food efficiency ratio
(%)
1.33e 10.58±
1.33 e
0.24a 2.80±
0.24 a
0.82a 4.62±
0.82 a
0.93a 10.75±
0.93 a
2.09c 3.40±
2.09 c
4.26a 23.42±
4.26 a
0.47a 2.99±
0.47 a
0.49bcd 3.48±
0.49 bcd
2.46b 15.65±
2.46 b
1.89a 10.57±
1.89 a
2.62cd 18.73±
2.62 cd
0.39a 2.83±
0.39 a
0.80bc 3.77±
0.80 bc
2.04b 14.82±
2.04 b
2.48ab 7.89±
2.48 ab
1.71ab 21.90±
1.71 ab
0.56a 2.98±
0.56 a
0.70b 3.86±
0.70 b
2.91b 15.62±
2.91 b
3.17ab 9.23±
3.17 ab
2.32bc 19.85±
2.32 bc
0.59a 2.99±
0.59 a
0.39d 3.24±
0.39 d
3.10b 15.67±
3.10 b
1.96ab 9.09±
1.96 ab
2.69abc 40.40±
2.69 abc
2.68abc 20.53±
2.68 abc
0.49a 2.98±
0.49 a
0.50cd 3.27±
0.50 cd
2.58b 15.64±
2.58 b
1.89ab 8.34±
1.89 ab
1.05cd 38.33±
1.05 cd
1.13cd 18.22±
1.13 cd
0.47a 2.69±
0.47 a
0.96bcd 3.48±
0.96 bcd
2.49b 14.12±
2.49 b
2.43ab 7.95±
2.43 ab
1.44cd 38.53±
1.44 cd
1.59cd 18.23±
1.59 cd
0.76a 3.01±
0.76 a
0.39d 3.00±
0.39 d
4.00b 15.79±
4.00 b
3.01b 6.69±
3.01 b
3.52d 36.27±
3.52 d
3.02d 16.35±
3.02 d
0.39a 3.06±
0.39 a
0.55cd 3.34±
0.55 cd
2.03b 16.06±
2.03 b
2.67b 6.98±
2.67 b
실험동물 각 군의 체중 변화에서 Initial body weight에는 각 군별로 유의한 차이가 없었으나, Final body weight에는 현저한 체중 변화를 나타내었다. 고지방식이군(HF)은 일반 식이군(NF)에 비해 체중이 1.45배 증가하였으며 이는 고지방식이에 의해 비만이 유도되었음을 제시한다. In the weight change of each group of experimental animals, there was no significant difference in the initial body weight for each group, but the final body weight showed a significant change in weight. The high fat diet group (HF) increased body weight by 1.45 times compared to the general diet group (NF), suggesting that obesity was induced by the high fat diet.
일년봉 추출물 투여 군(HF+E100, HF+E200), 보리지 추출물 투여 군(HF+B100, HF+B200)에서도 체중 감소 효과가 우수하였다. The weight loss effect was also excellent in the group administered the annual extract (HF+E100, HF+E200) and the group administered the borage extract (HF+B100, HF+B200).
다만, 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물 투여군(HF+TE100, HF+TE200)의 체중은 HF 군의 체중 보다 현저히 감소하여 일년봉 추출물 및 보리지 추출물을 단독으로 사용한 것에 비해, 상기 일년봉 추출물 및 보리지 추출물의 혼합물이 체중 감소 효과가 더욱 우수함을 확인하였다.However, the body weight of the group (HF+TE100, HF+TE200) administered with a mixture of annual bark extract, borage extract, cystocarp extract, suhocho extract and bibichu extract significantly decreased compared to the weight of the HF group, so Compared to using alone, it was confirmed that the mixture of the annual bark extract and the borage extract had more excellent weight loss effect.
3. 장기 및 지방 조직 무게3. Organ and fat tissue weight
채혈 후 실험동물을 희생시켜 신장, 비장, 간, 부고환 지방, 내장지방을 적출한 다음 생리식염수로 세척하여 여과지로 물기를 제거한 후 무게를 측정하였다.After blood collection, the test animals were sacrificed to extract kidney, spleen, liver, epididymis fat, and visceral fat, and then washed with physiological saline, dried with filter paper, and then weighed.
각 군의 장기 및 지방 조직 무게는 표 5에 나타내었다. 비장과 신장 무게에서 HF 군이 NF 군에 비해 유의하게 높았으나 추출물 투여 군은 HF 군에 비해 현저히 감소하였다. The weights of organs and adipose tissues of each group are shown in Table 5. In the weight of spleen and kidney, the HF group was significantly higher than that of the NF group, but the extract-administered group significantly decreased compared to the HF group.
간의 무게는 고지방식이를 섭취한 HF 군에서 현저히 증가하였다. 그러나 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물을 투여한 군에서 간의 무게가 HF 군에 비해 유의적으로 감소하였다. Liver weight was significantly increased in the HF group fed a high fat diet. However, the weight of liver was significantly decreased in the group administered with a mixture of annual extract, borage extract, cystic oleracea extract, sukhoi extract, and bibichu extract compared to the HF group.
이 결과는 고지방식이로 인하여 간조직에 콜레스테롤 및 중성지질이 축적되었으나 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물은 간의 비대 증상 완화에 효과가 우수함을 나타낸다.These results show that cholesterol and triglycerides were accumulated in the liver tissue due to a high fat diet, but a mixture of a year bong extract, borage extract, cystic vinegar extract, sukhoweed extract and bibichu extract was excellent in relieving liver hypertrophy symptoms.
일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물이 지방 조직에 미치는 영향을 조사하기 위하여 부고환 지방과 내장지방을 적출하여 무게를 측정하였다. 부고환 지방과 내장지방의 무게는 고지방식이 섭취에 의해 HF군이 현저히 증가하였으나 추출물 투여 군에서는 HF군에 비해 유의하게 감소하였다. 특히 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물은 지방 축적을 억제하여 우수한 체지방 감소 효과를 나타내었음을 알 수 있다.In order to investigate the effect of a mixture of annuus extract, borage extract, cystocarp extract, sukhoi extract and bibichu extract on adipose tissue, epididymal fat and visceral fat were excised and weighed. The weight of epididymal fat and visceral fat was significantly increased in the HF group by ingestion of the high fat diet, but significantly decreased in the extract administered group compared to the HF group. In particular, it can be seen that a mixture of an annual plant extract, a borage extract, a cystocarp extract, a sukhoi extract, and a bibichu extract exhibited excellent body fat reduction effect by inhibiting fat accumulation.
4. 혈액 생화학 지표 분석4. Blood biochemical indicator analysis
사육이 끝난 실험동물은 희생 전 12시간 동안 절식시킨 후 2,2,2-트리브로모에탄올(2,2,2-tribromoethanol, Sigma Aldrich) 및 2-메틸-2-부탄올(2-methyl-2-buthanol, Sigma Aldrich) 0.2 cc를 복강 주사하여 마취시켜 안와정맥채혈을 통해 공복 혈액을 채취하였으며 12,000g, 4℃에서 30분간 원심분리하여 혈청을 분리하였다. After breeding, the experimental animals were fasted for 12 hours before sacrifice, and then 2,2,2-tribromoethanol (Sigma Aldrich) and 2-methyl-2-butanol (2-methyl-2). -buthanol, Sigma Aldrich) 0.2 cc was intraperitoneally injected and anesthetized. Fasting blood was collected through orbital vein blood collection, and the serum was separated by centrifugation at 12,000g and 4℃ for 30 minutes.
혈액 생화학 지표로서 glucose(GLU), triglyceride(TG), total cholesterol(TC), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), alanine aminotransferase(ALT), aspartate aminotransferase(AST)의 수치는 Automated Clinical Chemistry Analyzer(FUJI DRI-CHEM NX500i)를 사용하여 분석하였다.Blood biochemical indicators include glucose (GLU), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase. The value of (AST) was analyzed using an Automated Clinical Chemistry Analyzer (FUJI DRI-CHEM NX500i).
(mg/dL)GLU
(mg/dL)
(mg/dL)TG
(mg/dL)
(mg/dL)TC
(mg/dL)
(mg/dL)HDL-C
(mg/dL)
(mg/dL)LDL-C
(mg/dL)
(U/L)ALT
(U/L)
(U/L)AST
(U/L)
1.53b 63.67±
1.53 b
7.94e 123.17±
7.94 e
7.86b 77.83±
7.86 b
4.23d 25.50±
4.23 d
11.46a 46.83±
11.46 a
11.14a 91.00±
11.14 a
17.67a 86.67±
17.67 a
7.61a 193.33±
7.61 a
9.63a 125.00±
9.63 a
1.03a 45.33±
1.03 a
26.55a 65.67±
26.55 a
17.13a 105.83±
17.13 a
4.58ab 74.00±
4.58 ab
11.48cd 174.50±
11.48 cd
5.68a 129.50±
5.68 a
7.69bc 36.57±
7.69 bc
19.79a 64.00±
19.79 a
10.50a 103.67±
10.50 a
12.10ab 75.33±
12.10 ab
7.58ab 181.50±
7.58 ab
6.42a 124.00±
6.42 a
5.65b 39.47±
5.65 b
13.63a 61.17±
13.63 a
22.22a 103.00±
22.22 a
10.12ab 74.33±
10.12 ab
13.42cd 173.83±
13.42 cd
11.50a 131.50±
11.50 a
4.58bc 34.17±
4.58 bc
17.56a 56.33±
17.56 a
21.66a 106.83±
21.66 a
6.11ab 79.33±
6.11 ab
8.33a 125.83±
8.33 a
4.69b 39.00±
4.69 b
22.28a 60.00±
22.28 a
20.98a 108.50±
20.98 a
8.72ab 75.00±
8.72 ab
13.60c 165.33±
13.60 c
8.67a 128.50±
8.67 a
2.17bc 33.80±
2.17 bc
14.74a 57.83±
14.74 a
14.92a 92.17±
14.92 a
7.77a 83.67±
7.77 a
9.66cd 174.83±
9.66 cd
6.57a 120.00±
6.57 a
4.89bc 36.50±
4.89 bc
11.00a 57.67±
11.00 a
12.25a 100.17±
12.25 a
5.77ab 70.33±
5.77 ab
11.54d 151.50±
11.54 d
11.04a 122.67±
11.04 a
4.64cd 30.63±
4.64 cd
20.03a 58.33±
20.03 a
22.21a 85.00±
22.21 a
일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물이 혈중 지질 농도 및 간 독성에 미치는 영향을 조사하기 위하여 혈청 중 GLU, TG, TC, HDL-C, LDL-C, ALT, AST를 측정하였다.GLU, TG, TC, HDL-C, LDL-C, ALT in serum to investigate the effects of a mixture of annuus extract, borage extract, cystaceae extract, sukhoi extract and bibichu extract on blood lipid concentration and liver toxicity. , AST was measured.
간 독성을 조사하기 위해 ALT와 AST를 측정하였으며 각 군별로 유의적인 차이가 나타나지 않아 추출물로 인한 독성이 나타나지 않음을 확인하였다.To investigate liver toxicity, ALT and AST were measured, and there was no significant difference between each group, so it was confirmed that no toxicity due to the extract appeared.
HDL-cholesterol(HDL-C)에서 HF과 추출물 투여군은 유의한 차이가 없었지만, HF군의 total cholesterol(TC)이 추출물 투여군 보다 유의하게 높아, HDL-cholesterol/total cholesterol에 대한 비율은 추출물 투여군에서 유의적으로 높았다. In HDL-cholesterol (HDL-C), there was no significant difference between the HF and the extract-administered group, but the total cholesterol (TC) of the HF group was significantly higher than that of the extract-administered group, and the ratio for HDL-cholesterol/total cholesterol was significant in the extract-administered group. The enemy was high.
LDL-cholesterol(LDL-C)은 추출물 투여군이 HF군에 비하여 감소되었고 혈당에서도 추출물 투여군은 HF군보다 유의적으로 감소되었다. 그중 HF+TE200군이 가장 낮았고, HF+B200군과 HF+TE100군이 다음으로 낮았다. 이것으로 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물은 혈중 콜레스테롤의 상승을 억제시키고 혈당을 감소시키는 효과가 우수하다고 사료된다. 따라서 일년봉 추출물 및 보리지 추출물의 혼합물은 혈중 지질 수치 개선으로 항비만 효과가 높다는 것을 나타낸다.LDL-cholesterol (LDL-C) was decreased in the extract-administered group compared to the HF group, and the extract-administered group also significantly decreased blood sugar levels compared to the HF group. Among them, the HF+TE200 group was the lowest, followed by the HF+B200 and HF+TE100 groups. As a result, it is considered that a mixture of annual extract, borage extract, cystweed extract, suhoweed extract and bibichu extract is excellent in inhibiting the rise of blood cholesterol and reducing blood sugar. Therefore, it is indicated that the mixture of annual bark extract and borage extract has high anti-obesity effect by improving blood lipid level.
5. Western blot analysis5. Western blot analysis
본 실시예에서는 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물을 투여한 C57BL/6J 마우스의 부고환 지방 조직에서 지방 생성에 관여하는 전사인자들의 발현을 확인하기 위해 western blot 분석을 통해 확인하였다. In this example, western blot to confirm the expression of transcription factors involved in adipogenesis in the epididymal adipose tissue of C57BL/6J mice administered with a mixture of an annual plant extract, a borage extract, a cystocarp extract, a susceptible extract, and a bibichu extract. It was confirmed through analysis.
부고환 지방조직에 PRO-PREP protein extraction solution을 첨가하고 균질화하여 -20℃에 30분간 반응시킨 후 12,000g, 4℃에서 30분간 원심분리하여 상등액을 얻어 Lowry 측정법으로 단백질을 정량하였다. 단백질은 SDS-PAGE로 분리하여 지방 생성에 관여하는 인자들의 항체와 반응시켜 단백질의 발현을 확인하였다.PRO-PREP protein extraction solution was added to epididymal adipose tissue, homogenized, reacted at -20°C for 30 minutes, centrifuged at 12,000g, 4°C for 30 minutes to obtain a supernatant, and the protein was quantified by the Lowry method. Protein was separated by SDS-PAGE, and the expression of the protein was confirmed by reacting with antibodies of factors involved in adipogenesis.
도 2는 adipogenesis에 관여하는 단백질의 발현 정도를 나타낸 것이다. PPARγ의 발현은 HF군과 비교하였을 때 HF+B200군의 발현이 유의적으로 감소되었고, HF+TE200군과 HF+E200군이 다음으로 감소되었다. C/EBPα의 발현은 HF군과 비교하였을 때 HF+TE200군의 발현이 유의적으로 감소되었으며 HF+G100군과 HF+B200군이 다음으로 감소되었다. PPARγ와 C/EBPα의 목표 단백질인 Adipoenctin의 발현은 HF군과 비교하였을 때 HF+TE200군의 발현이 유의적으로 증가되었으며 HF+B200군과 HF+E200군이 다음으로 증가되었다. 2 shows the level of expression of proteins involved in adipogenesis. When compared with the HF group, the expression of PPARγ was significantly decreased in the HF+B200 group, followed by the HF+TE200 group and the HF+E200 group. The expression of C/EBPα was significantly reduced in the HF+TE200 group compared to the HF group, and the HF+G100 group and the HF+B200 group were next decreased. The expression of Adipoenctin, the target protein of PPARγ and C/EBPα, was significantly increased in the HF+TE200 group compared to the HF group, followed by the HF+B200 group and the HF+E200 group.
이를 통해 일년봉 추출물 및 보리지 추출물을 단독 사용하는 경우 보다는 일년봉 추출물, 보리지 추출물, 낭아초 추출물, 수호초 추출물 및 비비추 추출물의 혼합물이 지방세포 분화를 보다 효과적으로 억제하여 우수한 항비만성을 나타내는 것을 확인하였다.Through this, it was confirmed that a mixture of an annual plant extract, a borage extract, a cystocarp extract, a sukhoi extract, and a bibichu extract more effectively inhibits adipocyte differentiation than when using an annual plant extract and a borage extract alone, thereby exhibiting excellent anti-obesity properties. I did.
6. 통계처리6. Statistical processing
본 실험에서 얻은 결과는 평균 ± 표준편차(mean ± S.D.)로 나타냈으며, 통계처리는 SPSS (17.0, Statistical Package for Social Science Inc., USA)를 이용하여 일원 변량분석(One way ANOVA)을 실시한 후 Duncan's multiple range test로 유의성을 p<0.05 수준에서 검증하였다.The results obtained in this experiment were expressed as mean ± standard deviation (mean ± SD), and statistical processing was performed after one-way ANOVA using SPSS (17.0, Statistical Package for Social Science Inc., USA). The significance was verified at the p<0.05 level with Duncan's multiple range test.
[실험예2: 기호성 테스트][Experimental Example 2: palatability test]
1. 관능성 평가 시험1. Sensory evaluation test
상기 E1 내지 E5에 대해 관능성 시험을 진행하였다. 관능성 실험을 진행하기 위해 E1 내지 E5를 차(茶)로 제조한 후, 10인의 시음자가 시음하여 맛과 향을 1 내지 10의 지수로 표현하였다.A sensory test was performed on the E1 to E5. In order to proceed with the sensory test, E1 to E5 were prepared as tea, and then taste and aroma were expressed by an index of 1 to 10 by tasting by 10 tasters.
그 평균값(0.5 반올림 적용)을 하기 표 3에 나타내었다. 상기 지수는 그 숫자가 높을수록 기호도가 높은 것이다.The average value (0.5 rounded off) is shown in Table 3 below. The higher the number, the higher the preference.
(단위: 지수)(Unit: index)
상기 표 7을 참조하면, E1 경우 일년봉 추출물의 맛은 좋게 평가되나, 일년봉 특유위 향이 기호도를 저하시켰고, 보리지 추출물의 혼합에 의하는 경우(E2)에도 향이 크게 개선되지는 않는 것을 알 수 있다. 또한 E3 혼합에 의하는 경우 복합 추출물로 향은 개선되었지만 떫고 시큼한 맛이 더해지는 것을 알 수 있다. 그에 반면, 복합 추출물 E4 및 E5에 의하는 경우 천연 추출물 특유의 향과 맛이 중화되면서 기호도가 상승함을 확인하였다.Referring to Table 7 above, in the case of E1, the taste of the annual bark extract was evaluated well, but the aroma specific to the annual bark lowered the preference, and it was found that the fragrance was not significantly improved even when mixed with borage extract (E2). I can. In addition, in the case of E3 mixing, it can be seen that the aroma is improved with the complex extract, but a bitter and sour taste is added. On the other hand, in the case of the complex extracts E4 and E5, it was confirmed that the taste and flavor of natural extracts were neutralized and the preference was increased.
따라서 복합 추출물 E4 및 E5에 의하는 경우, 보다 기호도 높은 향미와 맛으로 비만 피료 및 개선용 식품으로 제공할 수 있다.Therefore, in the case of complex extracts E4 and E5, it can be provided as a food for obesity treatment and improvement with a more palatable flavor and taste.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements by those skilled in the art using the basic concept of the present invention defined in the following claims are also present. It belongs to the scope of rights of
Claims (6)
상기 일년봉 추출물 100 중량부에 대하여, 보리지 추출물 80 내지 100 중량부, 낭아초 추출물 20 내지 40 중량부, 수호초 추출물 20 내지 40 중량부 및 비비추 추출물 20 내지 40 중량부를 포함하는
비만 치료 및 개선용 조성물.Erigeron annuus (L.) Pers extract, Borage officinalis extract, Indigofera pseudotinctoria extract, Pachysandra terminalis extract, and Hosta longipes extract,
Containing 80 to 100 parts by weight of borage extract, 20 to 40 parts by weight of cystocarp extract, 20 to 40 parts by weight of sukhoi extract, and 20 to 40 parts by weight of bibichu extract based on 100 parts by weight of the annual extract extract
Composition for treating and improving obesity.
상기 조성물은 PPARγ와 C/EBPα의 발현을 억제하여, 항비만 효과가 우수한
비만 치료 및 개선용 조성물.The method of claim 1,
The composition inhibits the expression of PPARγ and C/EBPα, and has excellent antiobesity effect
Composition for treating and improving obesity.
상기 추출물은 물, C₁ 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출하는
비만 치료 및 개선용 조성물.The method of claim 1,
The extract is extracted using an extraction solvent selected from the group consisting of water, C₁ to C6 lower alcohol, and mixtures thereof.
Composition for treating and improving obesity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190028351A KR102193317B1 (en) | 2019-03-12 | 2019-03-12 | Composition for obesity treatment and improvement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190028351A KR102193317B1 (en) | 2019-03-12 | 2019-03-12 | Composition for obesity treatment and improvement |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200109178A KR20200109178A (en) | 2020-09-22 |
KR102193317B1 true KR102193317B1 (en) | 2020-12-22 |
Family
ID=72706785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190028351A KR102193317B1 (en) | 2019-03-12 | 2019-03-12 | Composition for obesity treatment and improvement |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102193317B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520588A (en) | 2004-11-18 | 2008-06-19 | ビオファーマコペ デジン アンテルナショナル インク. | Plant extract and its dermatological usage |
KR101620077B1 (en) * | 2013-11-12 | 2016-05-12 | 주식회사 파미니티 | Composition for Improving, Preventing or Treating Metabolic Diseases comprising Extracts from Borage officinalis |
KR101942429B1 (en) | 2017-10-31 | 2019-01-25 | 동의대학교 산학협력단 | Composition comprising Morifolium extract component effective for preventing and treatingarthritis |
KR102094001B1 (en) | 2018-08-02 | 2020-03-26 | 동의대학교 산학협력단 | An anti-obesity composition comprising Gelidium amansii extract and Salicornia europaea extract |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100997912B1 (en) * | 2008-06-27 | 2010-12-03 | 한국 한의학 연구원 | Compositions and functional food for prevention and treatment of diabetic complications |
KR20150055876A (en) | 2013-11-14 | 2015-05-22 | 주식회사 엘지생활건강 | Composition for reducing body-fat and weight |
KR101635082B1 (en) * | 2013-12-18 | 2016-06-30 | 한국식품연구원 | Pharmaceutical or food composition having TGR5 agonist activity |
KR101595515B1 (en) | 2014-11-10 | 2016-02-19 | 주식회사 엔에스웰니스 | Composition for Preventing or Treating Stress-Related Diseases Comprising Annual fleabane Extracts as Active Ingredients |
KR101941183B1 (en) * | 2016-10-24 | 2019-04-12 | 주식회사 바이오포트코리아 | Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof |
KR20190064907A (en) * | 2017-12-01 | 2019-06-11 | 주식회사 엔에스웰니스 | Composition for obesity treatment and improvement |
-
2019
- 2019-03-12 KR KR1020190028351A patent/KR102193317B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520588A (en) | 2004-11-18 | 2008-06-19 | ビオファーマコペ デジン アンテルナショナル インク. | Plant extract and its dermatological usage |
KR101620077B1 (en) * | 2013-11-12 | 2016-05-12 | 주식회사 파미니티 | Composition for Improving, Preventing or Treating Metabolic Diseases comprising Extracts from Borage officinalis |
KR101942429B1 (en) | 2017-10-31 | 2019-01-25 | 동의대학교 산학협력단 | Composition comprising Morifolium extract component effective for preventing and treatingarthritis |
KR102094001B1 (en) | 2018-08-02 | 2020-03-26 | 동의대학교 산학협력단 | An anti-obesity composition comprising Gelidium amansii extract and Salicornia europaea extract |
Non-Patent Citations (3)
Title |
---|
MARRELLI M. ET AL., J SCI FOOD AGRIC. 2014 AUG, 94(11): 2217_24(2014.02.18) |
개망초 추출 분말의 In Vitro에서의 항산화 특성과 고지방식이로 유도된 Mice의 혈청지질 수준에 미치는 영향, 한국식품영양학회지, 28(3), pp.387-395(2015) 1부.* |
지질분해효소 저해물질 함유 약용식물의 선발 및 저해물질 추출조건 . 한국약용작물학회지. 20(1), pp.1-7(2012.02.) 1부.* |
Also Published As
Publication number | Publication date |
---|---|
KR20200109178A (en) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumar et al. | Recent trends in potential traditional Indian herbs Emblica officinalis and its medicinal importance | |
KR101176590B1 (en) | Herbal Composition for Removing Hangover and Beverage Containing the Same | |
Adkar et al. | Pandanus odoratissimus (Kewda): A review on ethnopharmacology, phytochemistry, and nutritional aspects | |
JP6929954B2 (en) | Method for improving gingival inflammation and periodontitis by antibacterial, antioxidant, anti-inflammatory, suppression and regeneration of alveolar bone loss of Moringa leaf extract and Tochu extract complex | |
KR20160087114A (en) | Food additive containing flowers | |
KR101817055B1 (en) | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities | |
KR20160087112A (en) | Flower tea and method for manufacturing therof | |
Gautam et al. | Detailed study on therapeutic properties, uses and pharmacological applications of safflower (Carthamus tinctorius L.) | |
Milind et al. | Walnut: not a hard nut to crack | |
KR20220078140A (en) | Composition for preventing or improving respiratory disease | |
CN107156829A (en) | A kind of full nutrition formula food suitable for hepatopath | |
KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
Ravindran et al. | Under-utilized herbs and spices | |
US7399491B2 (en) | Health promoting functional foods fortified with herbs | |
KR102193317B1 (en) | Composition for obesity treatment and improvement | |
KR101310019B1 (en) | Namhae artemisia tea improved in palatability and functionality and method thereof | |
Yadav et al. | Trigonella foenum‑graecum: A herbal plant review | |
KR101768612B1 (en) | Food composition for improving liver function and method of health tea using thereof | |
Ravindran et al. | Other herbs and spices: achiote to Szechuan pepper | |
De et al. | Nutrient rich foods in human diet as immunity boosters | |
Lim | Opuntia ficus-indica | |
KR20140062230A (en) | Fermented bellflower pills and preparation thereof | |
KR101544000B1 (en) | A composition comprising extracts of herbal mixture having skin whitening effect | |
Ilyina et al. | Alimentary and medicinal plants in functional nutrition | |
Dwivedi | Vegetal Taste Modifiers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |